

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-660

STATISTICAL REVIEW(S)



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Pharmacoeconomics and Statistical Science
Office of Biostatistics

STATISTICAL REVIEW AND EVALUATION CLINICAL STUDIES

NDA/Serial Number: 21-660 / N000

Drug Name: Abraxane™ (ABI-007) [unit strength = 100 mg/50 mL vial]

Indication(s): Metastatic Breast Cancer

Applicant: American BioScience, Inc.

Date(s): Submission Date: March 8, 2004
PDUFA Date: January 8, 2005

Review Priority: Standard.

Biometrics Division: Division of Biometrics I (HFD-710)

Statistical Reviewer: Peiling Yang, Ph.D.

Concurring Reviewers: Team Leader: Rajeshwari Sridhara, Ph.D.
Acting Division Director: Kooros Mahjoob, Ph.D.

Medical Division: Division of Oncology Drug Product (HFD-150)

Clinical Team: Reviewer: Nancy Scher, M.D.
Team Leader: Ramzi Dagher, M.D.

Project Manager: Ms. Sheila Ryan

Keywords: Superiority.

TABLE of CONTENTS

1	EXECUTIVE SUMMARY	1
1.1	CONCLUSIONS AND RECOMMENDATIONS	1
1.2	BRIEF OVERVIEW OF CLINICAL STUDIES	1
1.3	STATISTICAL ISSUES AND FINDINGS	1
2	INTRODUCTION	4
2.1	OVERVIEW	4
2.2	DATA SOURCES	6
3	STATISTICAL EVALUATION	7
3.1	EVALUATION OF EFFICACY	7
3.1.1	<i>Study Design</i>	7
3.1.2	<i>Efficacy Endpoints</i>	8
3.1.3	<i>Hypothesis Test and Sample Size Considerations</i>	9
3.1.4	<i>Statistical Analysis Plan</i>	9
3.1.5	<i>Sponsor's Results and Reviewer's Comments</i>	12
3.1.5.1	Patient Disposition	12
3.1.5.2	Analysis Population	13
3.1.5.3	Demographics	14
3.1.5.4	Other Baseline Characteristics	15
3.1.5.5	Primary Endpoint: Reconciled Target Lesion Response Rate (<i>recTLRR</i>)	17
3.1.5.6	Secondary Endpoint: Investigator-Assessed Overall Response Rate (<i>invORR</i>)	21
3.1.5.7	Secondary Endpoint: Duration of Response	23
3.1.5.8	Secondary Endpoint: Time to Disease Progression	28
3.1.5.9	Secondary Endpoint: Overall Survival	32
3.2	EVALUATION OF SAFETY	33
4	FINDINGS IN SPECIAL/SUBGROUP POPULATIONS	34
4.1	GENDER, RACE AND AGE	34
4.1.1	<i>Gender</i>	34
4.1.2	<i>Race</i>	34
4.1.3	<i>Age</i>	35
4.2	OTHER SPECIAL/SUBGROUP POPULATIONS	36
4.2.1	<i>Line of Therapy</i>	36
4.2.2	<i>Prior Anthracycline Therapy</i>	37
4.2.3	<i>Patient Population in Taxol Indication</i>	38
4.2.4	<i>Country</i>	39
5	SUMMARY AND CONCLUSIONS	40
5.1	STATISTICAL ISSUES AND COLLECTIVE EVIDENCE	40
5.2	CONCLUSIONS AND RECOMMENDATIONS	41

LIST OF TABLES

TABLE 1: REVIEWER'S RESULTS OF FDA-CONFIRMED <i>recTLRR</i> (ALL RANDOMIZED PATIENTS).....	2
TABLE 2: FACTORS OF POTENTIAL INFLUENCE ON RESPONSE.....	11
TABLE 3: SPONSOR'S SUMMARY OF PATIENT DISPOSITION.....	12
TABLE 4: SPONSOR'S SUMMARY OF PATIENT POPULATIONS FOR ANALYSIS.....	13
TABLE 5: SPONSOR'S RESULTS OF PATIENT DEMOGRAPHICS (SPONSOR-DEFINED ITT POPULATION).....	14
TABLE 6: SPONSOR'S RESULTS OF INITIAL DIAGNOSIS OF BREAST CANCER (SPONSOR-DEFINED ITT POPULATION).....	15
TABLE 7: SPONSOR'S RESULTS OF PRIOR THERAPIES AT BASELINE (ON SPONSOR'S ITT POPULATION).....	16
TABLE 8: SPONSOR'S RESULTS OF HISTORY OF PRIOR METASTATIC TREATMENTS AT BASELINE (ON SPONSOR'S ITT POPULATION).....	16
TABLE 9: SPONSOR'S RESULTS OF RECONCILED TARGET LESION RESPONSE BY RESPONSE TYPE (SPONSOR- DEFINED ITT POPULATION).....	17
TABLE 10: SPONSOR'S RESULTS OF <i>recTLRR</i> (SPONSOR-DEFINED ITT POPULATION).....	18
TABLE 11: SPONSOR'S RESULTS OF <i>recTLRR</i> IN PATIENTS RECEIVING 1 ST -LINE THERAPY (SPONSOR- DEFINED ITT POPULATION).....	18
TABLE 12: SPONSOR'S RESULTS OF <i>recTLRR</i> IN PATIENTS WHO MET TAXOL INDICATION (SPONSOR- DEFINED ITT POPULATION).....	19
TABLE 13: DISCREPANCY IN RESPONSE STATUS BETWEEN FDA AND SPONSOR.....	19
TABLE 14: REVIEWER'S RESULTS OF FDA-CONFIRMED <i>recTLRR</i> (ALL RANDOMIZED PATIENTS).....	20
TABLE 15: REVIEWER'S RESULTS OF FDA-CONFIRMED <i>recTLRR</i> IN PATIENTS RECEIVING 1 ST -LINE THERAPY (ALL RANDOMIZED PATIENTS).....	20
TABLE 16: REVIEWER'S RESULTS OF FDA-CONFIRMED <i>recTLRR</i> IN PATIENTS WHO MET TAXOL INDICATION (ALL RANDOMIZED PATIENTS).....	21
TABLE 17: SPONSOR'S COMPARISON OF <i>invORR</i> AND <i>recTLRR</i>	21
TABLE 18: SPONSOR'S RESULTS OF INVESTIGATOR-ASSESSED OVERALL RESPONSE BY RESPONSE TYPE (ON SPONSOR-DEFINED ITT POPULATION).....	22
TABLE 19: SPONSOR'S RESULTS OF <i>invORR</i> (SPONSOR-DEFINED ITT POPULATION).....	22
TABLE 20: SPONSOR'S RESULTS OF <i>invORR</i> IN PATIENTS RECEIVING 1 ST -LINE THERAPY (SPONSOR-DEFINED ITT POPULATION).....	23
TABLE 21: REVIEWER'S RESULTS OF <i>invORR</i> (ALL RANDOMIZED PATIENTS).....	23
TABLE 22: SPONSOR'S RESULTS OF DURATION OF RESPONSE ON RESPONDERS WHO HAD RECONCILED TARGET LESION RESPONSE.....	24
TABLE 23: SPONSOR'S RESULTS OF DURATION OF RESPONSE ON RESPONDERS WHO HAD OVERALL RESPONSE BASED ON INVESTIGATOR RESPONSE ASSESSMENT DATASET INCLUDING CYCLES > 6.....	25
TABLE 24: REVIEWER'S RESULTS DURATION OF RESPONSE ON FDA-CONFIRMED RESPONDERS (BASED ON RECONCILED ASSESSMENT THROUGH CYCLE 6).....	25
TABLE 25: REVIEWER'S RESULTS OF DURATION OF RESPONSE ON FDA-CONFIRMED RESPONDERS (BASED ON INVESTIGATOR'S ASSESSMENT INCLUDING CYCLES BEYOND 6 OR WORLD CARE ASSESSMENT THROUGH CYCLE 6).....	27
TABLE 26: SPONSOR'S RESULTS OF TIME TO DISEASE PROGRESSION.....	29
TABLE 27: REVIEWER'S RESULTS OF TIME TO DISEASE PROGRESSION (ALL RANDOMIZED PATIENTS).....	30
TABLE 28: SPONSOR'S RESULTS OF OVERALL SURVIVAL ON SPONSOR-DEFINED ITT POPULATION.....	32
TABLE 29: REVIEWER'S RESULTS OF OVERALL SURVIVAL (ALL RANDOMIZED PATIENTS).....	33
TABLE 30: SUBGROUP ANALYSIS BY RACE: REVIEWER'S EXPLORATORY RESULTS OF FDA-CONFIRMED <i>recTLRR</i> (ALL RANDOMIZED PATIENTS).....	34
TABLE 31: SUBGROUP ANALYSIS BY AGE: REVIEWER'S EXPLORATORY RESULTS OF FDA-CONFIRMED <i>recTLRR</i> (ALL RANDOMIZED PATIENTS).....	35
TABLE 32: SUBGROUP ANALYSIS BY LINE OF THERAPY: REVIEWER'S EXPLORATORY RESULTS OF FDA- CONFIRMED <i>recTLRR</i> (ALL RANDOMIZED PATIENTS).....	36
TABLE 33: SUBGROUP ANALYSIS BY PRIOR ANTHRACYCLINE THERAPY: REVIEWER'S EXPLORATORY RESULTS OF FDA-CONFIRMED <i>recTLRR</i> (ALL RANDOMIZED PATIENTS).....	37

TABLE 34: SUBGROUP ANALYSIS BY TAXOL INDICATION: REVIEWER'S EXPLORATORY RESULTS OF FDA-
CONFIRMED *RECTLRR* (ALL RANDOMIZED PATIENTS)..... 38
TABLE 35: SUBGROUP ANALYSIS BY COUNTRY: REVIEWER'S EXPLORATORY RESULTS OF FDA-CONFIRMED
RECTLRR (ALL RANDOMIZED PATIENTS)..... 39

APPEARS THIS WAY
ON ORIGINAL

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.